Two Takayasu arteritis patients successfully treated with rituximab

Clinical Rheumatology

Volumn 33, Issue 8, 2014, Pages 1183-1184

  Caltran, E ^a   Di Colo, G ^a   Ghigliotti, G ^b   Capecchi, R ^a   Catarsi, E ^a   Puxeddu, I ^a   Migliorini, P ^a   Tavoni, A ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

B lymphocytes; Rituximab; Takayasu arteritis

Indexed keywords

IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; RITUXIMAB;

ADULT; CASE REPORT; FEMALE; HUMAN; TAKAYASU ARTERITIS; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; TAKAYASU ARTERITIS; TREATMENT OUTCOME;

EID: 84904417046     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-014-2506-5     Document Type: Review

References (11)

1. Arnaud L, Haroche J, Mathian A, Gorochov G, Amoura Z (2011) Pathogenesis of Takayasu's arteritis: a 2011 update. Autoimmun Rev 11:61-67
2. Sima D, Thiele B, Turowski A,WilkeK, Hiepe F, Volk D et al (1994) Anti-endothelial antibodies in Takayasu arteritis. Arthritis Rheum 37:441-443 (Pubitemid 24093641)
3. Inder SJ, Bobryshev YV, Cherian SM, Wang AY, Lord RS, Masuda K et al (2000) Immunophenotypic analysis of the aortic wall in Takayasu's arteritis: involvement of lymphocytes, dendritic cells and granulocytes in immuno- inflammatory reactions. Cardiovasc Surg 8:141-148 (Pubitemid 30110714)
4. Sharma BK, Jain S, Suri S, Numano F (1996) Diagnostic criteria for Takayasu arteritis. Int J Cardiol 54:S141-S147
5. Comarmond C, Plaisier E, Dahan K, Mirault T, Emmerich J, Amoura Z et al (2012) Anti TNF-á in refractory Takayasu's arteritis: cases series and review of the literature. Autoimmun Rev 11:678-684
6. Quartuccio L, Schiavon F, Zuliani F, Carraro V, Catarsi E, Tavoni AG et al (2012) Long-term efficacy and improvement of health-related quality of life in patients with Takayasu's arteritis treated with infliximab. Clin Exp Rheumatol 30(6):922-928
7. Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P (2004) Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 50:2296-2304 (Pubitemid 38924409)
8. Salvarani C,Magnani L, CatanosoM, Pipitone N, Versari A, Dardani L et al (2012) Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology 51:151-156
9. Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T (2008) Successful treatment of a patient with Takayasu arteritis using a humanized anti interleukin-6 receptor antibody. Arthritis Rheum 58:1197-1200 (Pubitemid 351564023)
10. Galarza C, Valencia D, Tobón GJ, Zurita L, Mantilla RD, Pineda-Tamayo R et al (2008) Should rituximab be considered as the firstchoice treatment for severe autoimmune rheumatic diseases? Clin Rev Allergy Immunol 34:124-128
11. Hoyer BF, Mumtaz IM, Loddenkemper K, Bruns A, Sengler C, Hermann KG et al (2012) Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis 71:75-79